11 results about "Ischaemic encephalopathy" patented technology

The present technology comprises isolated endothelial progenitor cell (EPC) populations comprising PROCR+ / - PDGFRA+ / - EPCs and mesenchymal stem cell (MSC) populations, and methods of making and use thereof in treating hypoxic-ischemic encephalopathy (HIE) or brain injury in a subject.

The invention pertains to a new computer-implemented method for processing an EEG signal, that makes it possible to extract information about cerebral damage in full-term babies, born in asphyxia context, for help in an indication for treatment of hypoxic-ischemic encephalopathy (HIE), by computing a power spectral density (PSD) of an EEG signal, transforming the PSD by a mathematical function, processing the transformed values by data binning, and creating a probability distribution of the durations of the binned values.

The invention belongs to the technical field of medicines, and particularly relates to application of lycium barbarum glycopeptide in preparation of a medicine for preventing or treating ischemic encephalopathy. Specifically, the invention relates to application of lycium barbarum glycopeptide in preparation of drugs for preventing or treating cerebral arterial thrombosis. Pharmacological experiments show that the lycium barbarum glycopeptide has an obvious treatment effect on dyskinesia and neurological impairment of focal ischemic stroke model rats caused by middle cerebral artery ischemia reperfusion; the compound also has a remarkable improvement effect on learning and memory cognitive impairment of the model rat, so that the compound can be used for preparing medicines for preventing or treating related ischemic encephalopathy.

The invention relates to the technical field of medical instruments, and discloses a neonatal ice cap for treating hypoxic ischemic encephalopathy, which comprises an ice cap body, a water changing head, a valve shell which is arranged on the ice cap body and is used for exchanging cooling liquid, and a sealing mechanism and a water stopping assembly which are arranged in the valve shell, a valve seat is fixedly installed in the valve shell, a water inlet channel used for circulation of cooling liquid is formed in the valve seat, and an elastic corrugated rubber ring is arranged in the valve seat. According to the neonatal ice cap for treating the hypoxic ischemic encephalopathy, cooling liquid in the ice cap body can be replaced through the water changing head, through the arrangement, cold therapy interruption caused by inconvenient replacement due to the fact that a traditional ice cap loses the original cooling effect is avoided, and it is ensured that a neonatal can continuously receive effective head cold therapy in the treatment period; and in addition, the continuous and stable cold therapy environment is beneficial for reducing the discomfort of the newborns and promoting the improvement of treatment compliance.

The present technology includes an isolated population of endothelial progenitor cells (EPCs) comprising PROCR + / -PDGFRA + / -EPC and a population of mesenchymal stem cells (MSCs), as well as methods of preparation and use thereof in the treatment of hypoxic ischemic encephalopathy (HIE) or brain injury in a subject.

The invention belongs to the technical field of medicines, and particularly relates to application of novel glycyrrhizol in preparation of products for preventing or treating ischemic encephalopathy, and the ischemic encephalopathy comprises cerebral thrombosis, cerebrovascular stenosis / occlusion and cerebral atherosclerosis. According to the application disclosed by the invention, the novel glycyrrhizol is used for treating the ischemic encephalopathy for the first time, and experiments show that the novel glycyrrhizol has a remarkable treatment effect on the ischemic encephalopathy, can be used for obviously improving behavioral scores, cerebral thrombosis and vascular diameter conditions after ischemia and reducing the volume of cerebral infarction, and has a good treatment effect on cerebral thrombosis and middle artery embolism. Therefore, the compound can be used for preparing medicines for preventing or treating ischemic encephalopathy.

The present invention provides an application of antimicrobial peptide MU1, especially an application in preparing a drug for treating hypoxic-ischemic encephalopathy and a drug for protecting neurons, and belongs to the field of biomedicine. The present invention verifies through experiments that antimicrobial peptide MU1 has the effects of alleviating the symptoms of hypoxic-ischemic encephalopathy and protecting neurons, and can be used to prepare a drug for treating hypoxic-ischemic brain injury, especially neonatal hypoxic-ischemic encephalopathy. The antimicrobial peptide MU1 has good therapeutic effect and high safety, filling the gap in the prior art that neonatal hypoxic-ischemic encephalopathy has no drug to treat it, and has good application prospects.

The present application provides the use of aucubin or the combination of aucubin and ACA in the preparation of a medicament for treating ischemic brain injury, in particular acute cerebral ischemia-reperfusion injury. The present application first discovers that aucubin or the combination of aucubin and ACA can increase the blood flow of the ischemic side after ischemic brain injury in mice; significantly reduce the cerebral infarction volume; improve the cognitive and motor function of mice after ischemic brain injury; reduce the degree of injury caused by cerebral ischemia, significantly improve the degree of neuronal necrosis of brain tissue after ischemia; significantly increase the survival rate of HT22 cells after oxygen-glucose deprivation and reperfusion injury, reduce intracellular Ca 2+ fluorescence intensity, and inhibit cell apoptosis.

The invention provides application of an antibacterial peptide MU1, in particular to application in preparation of drugs for treating hypoxic ischemic encephalopathy and neuronal protection, and belongs to the field of biomedicine. Experiments prove that the antibacterial peptide MU1 has the effects of relieving symptoms of hypoxic-ischemic encephalopathy and protecting neurons, can be used for preparing drugs for treating hypoxic-ischemic brain injury, especially for treating neonatal hypoxic-ischemic encephalopathy, and is relatively good in treatment effect, high in safety and low in cost. The blank that in the prior art, neonatal hypoxic ischemic encephalopathy cannot be treated with medicine is filled up, and good application prospects are achieved.

The invention pertains to a new computer-implemented method for processing an EEG signal, that makes it possible to extract information about cerebral damage in full-term babies, born in asphyxia context, for help in an indication for treatment of hypoxic-ischemic encephalopathy (HIE), by computing a power spectral density (PSD) of an EEG signal, transforming the PSD by a mathematical function, processing the transformed values by data binning, and creating a probability distribution of the durations of the binned values.

The present invention relates to the field of medical technology. The present invention provides use of butyric acid and its derivatives or pharmaceutically acceptable salts thereof in preparing products for treating hypoxic-ischemic encephalopathy. For the first time, butyric acid-producing bacteria and abnormal butyric acid metabolic pathways were found in feces of HIBD model rats. Further studies have found that the use of butyric acid and its derivatives or pharmaceutically acceptable salts thereof to intervene in newborn HIBD model rats can restore pathological damage to the cerebral cortex and hippocampus of the HIBD rats and behavioral studies related to learning and memory, and promote the recovery of intestinal contents and metabolic pathway-related flora, indicating that butyric acid and its derivatives or pharmaceutically acceptable salts thereof have the use of preparing products for alleviating, assisting in the treatment or treating hypoxic-ischemic encephalopathy.